Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
25 sept. 2024 07h07 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured approximately $400 million in orders in 2024 and 2025 associated with its...
Global Diagnostics and Therapeutics for HIV Market Expected to Reach $39.3 Billion by 2028: Advancements in Diagnostic Technologies Drive Growth
01 nov. 2023 05h58 HE
|
Research and Markets
Dublin, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The "Diagnostics and Therapeutics for HIV: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global diagnostics and...
Global HIV Drugs Market Research Report 2023-2031: Antiretroviral Therapy (ART) Emerging as Pivotal Tool in Managing HIV and Enhancing Well-Being
03 oct. 2023 06h58 HE
|
Research and Markets
Dublin, Oct. 03, 2023 (GLOBE NEWSWIRE) -- The "Global HIV Drugs Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global HIV drugs market value...
AIDSVu Releases New Data Showing Significant Inequities in PrEP Use Among Black and Hispanic Americans
29 juil. 2022 12h30 HE
|
AIDSVu
ATLANTA, July 29, 2022 (GLOBE NEWSWIRE) -- Today, AIDSVu released the first-ever publicly available state-level PrEP use data and maps by race/ethnicity from 2012 to 2021, showing that while PrEP...
Exavir Therapeutics announces publication of preclinical data for ultra-long-acting dolutegravir prodrug XVIR-120
09 juin 2022 07h00 HE
|
Exavir Therapeutics
Ultra-long-acting plasma pharmacokinetics and biodistribution to tissues of interest demonstrated in three species Injections were well tolerated with no adverse findings in preliminary toxicology...
Exavir Therapeutics Completes $4M Seed Financing from Key Investors
23 mai 2022 07h00 HE
|
Exavir Therapeutics
NEW YORK and OMAHA, Neb., May 23, 2022 (GLOBE NEWSWIRE) -- Exavir Therapeutics, a company dedicated to transforming the lives of people living with or at risk of acquiring HIV, today announced that...
Global and Historical Trends - HIV Epidemiology Forecasts to 2029
22 févr. 2022 05h53 HE
|
Research and Markets
Dublin, Feb. 22, 2022 (GLOBE NEWSWIRE) -- The "Human Immunodeficiency Virus (HIV) - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. The total prevalent...
Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV
16 sept. 2021 07h30 HE
|
Exavir Therapeutics
With a single administration, XVIR-210, a nano-formulated prodrug of tenofovir, provided drug levels sufficient for chronic HBV treatment, HIV treatment, and HIV prophylaxis for over two months in...
Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral
08 juin 2021 07h00 HE
|
Exavir Therapeutics
With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in animal models Studies...
APLA Health & Wellness to Open New Long Beach Health Center in January 2016
29 sept. 2015 14h23 HE
|
AIDS Project Los Angeles
LONG BEACH, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) -- APLA Health & Wellness (APLAHW) is proud to announce that we have been funded to open a new federally qualified health center in Long Beach...